Dana-Farber/Harvard Cancer Center, Boston, MA
David F. McDermott , Jae-Lyun Lee , Georg A. Bjarnason , James M. G. Larkin , Rustem Gafanov , Mark D. Kochenderfer , Niels Viggo Jensen , Frede Donskov , Jahangeer Malik , Alexandr Poprach , Scott S. Tykodi , Teresa Alonso Gordoa , Daniel C. Cho , Poul F. Geertsen , Miguel Angel Climent Duran , Christopher Di Simone , Xiaoqi Du , Rodolfo F. Perini , Karla Rodriguez-Lopez , Michael B. Atkins
Background: KEYNOTE-427 (NCT02853344), an open-label, single-arm, phase 2 study, showed clinical activity of first-line pembro monotherapy in patients (pts) with ccRCC (cohort A). Previous studies in RCC and immune-oncology suggest depth of response may correlate with long-term benefit. Association between depth of response and OS, along with updated efficacy and safety for cohort A of KEYNOTE-427, are presented. Methods: Pts with histologically confirmed ccRCC, measurable disease (RECIST v1.1), and no prior systemic therapy received pembro 200 mg IV Q3W for 2 y or until progressive disease, unacceptable toxicity, or withdrawal. End points: ORR (primary), DOR, and PFS (RECIST v1.1); OS, and safety. Association between depth of response (maximum reduction from baseline in the sum of target lesions) and OS was evaluated using Cox proportional hazards model with target lesion reduction group as time-varying covariate. Results: 110 pts enrolled; median time from enrollment to data cutoff was 23.1 (range, 16.7-27.5) mo. Overall, 38.2% of pts had favorable and 61.2% had intermediate/poor IMDC risk. ORR was 36.4% (95% CI, 27.4-46.1; 3 CRs, 37 PRs); median (range) DOR was not reached (2.3-23.5+ mo); 64.0% had a DOR ≥12 mo. Median PFS was 7.1 mo (95% CI, 5.6-11.0) and median OS was not reached; 18-mo PFS and OS rates were 26.6% and 80.0%, respectively. 69.1% had some reduction in target lesions. Pts with > 60% reduction in target lesions had a greater probability of survival than pts with a ≤60% reduction (Table). ORR observed in IMDC favorable and intermediate/poor risk was 31.0% and 39.7%, respectively; 18-mo OS rate was 95.2% for favorable and 70.5% for intermediate/poor IMDC risk. Treatment-related AEs (TRAEs) occurred in 81.8% of pts, primarily fatigue (29.1%) and pruritus (28.2%). Grade ≥3 TRAEs occurred in 29.1% of pts; 1 pt died of treatment-related pneumonitis. Conclusions: First-line pembro monotherapy was tolerable and showed promising antitumor activity in advanced ccRCC. In general, pts who had greater reductions in target lesions demonstrated a trend toward improved OS; pts with reduction of tumor burden ≥80% had comparable long term outcomes to those who achieved a RECIST 1.1 defined CR. Clinical trial information: NCT02853344.
Depth of response, % | Association Between Depth of Response and Risk for Death N = 110 | |
---|---|---|
n (%) | HR (95% CI) | |
CR | 3 (2.7) | 0 (0.0-NE) |
–100 to –80 | 16 (14.5) | 0 (0.0-NE) |
<–80 to –60 | 13 (11.8) | 0.39 (0.04-3.54) |
<–60 to –30 | 18 (16.4) | 1.57 (0.44-5.65) |
<–30 to < 0 | 26 (23.6) | Reference |
0 to < 20 | 17 (15.5) | 1.70 (0.52-5.59) |
≥20 | 14 (12.7) | 2.04 (0.61-6.88) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Manish A. Shah
2023 ASCO Annual Meeting
First Author: Brian I. Rini
2019 ASCO Annual Meeting
First Author: Jae-Lyun Lee
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Lorenza Rimassa